Oncology CRO & Drug Development Services
Medelis is a single-source provider for oncology CRO and oncology drug development services, providing a total solution for biotechnology and pharmaceutical companies seeking rapid drug development and approval. Our offerings include
- Oncology clinical trial management and design, including strategic plans for regulatory approval from Phase I through NDA
- Preclinical program analysis, design, management and execution
- Preclinical program review and “gap analysis”
- Site identification, qualification, management, contracting and payment
- Investigator identification & recruitment
- Patient recruitment & accrual strategies
- Project management & monitoring of clinical studies
Learn more about our oncology CRO services »
World-Class Expertise
We specialize in oncology clinical trials, which are usually longer and more complex than those targeting other diseases. Medelis' medical founders, team physicians and clinical trial management physicians are internationally-recognized oncology thought and opinion leaders who understand the future of personalized medicine and threshold of credibility trials. Our extensive worldwide contacts and involvement with the oncology clinical research community keep us close to research trends and developments. And our entire management team, project managers and CRAs all have deep oncology experience to complement their operational and technical skills.
More about our focus on oncology & targeted therapeutics »
Clinical Answers Faster
Medelis has the breadth of capabilities, depth of expertise, strategic partnerships, focus and agility to deliver accurate results quickly. We create superior research designs that yield the right data the first time. And we're organized to set up trials and recruit patients with exceptional speed.
With this approach, we can deliver faster, more accurate results and help speed our clients' drugs to market.
Recent News: Cancer Researcher Dan Von Hoff, M.D. Advocates for “Context of Vulnerability,” A Powerful New Paradigm for Targeted Drug Development
Dr. Daniel Von Hoff and his team at TGen are fervent believers in a new approach to developing novel therapies for patients with pancreatic cancer. They are guided by a rationale dubbed the "context of vulnerability," which he explains in the latest issue of Peer Perspectives in Oncology.
Phoenix AZ —February 17, 2009 — Today, Medelis has published a free new issue of Peer Perspectives in Oncology, "Context of Vulnerability: A Powerful New Paradigm for Targeted Drug Development." In this extensive interview, renowned oncology investigator Daniel D. Von Hoff, M.D., a founder of Medelis and a member the National Cancer Advisory Board, advocates for powerful new drug development paradigm that is generating impressive results in the war on pancreatic cancer, the most deadly of all cancers.
Medelis Publishes “The Lost Opportunity in Phase I Oncology Trials"
While most biotechnology companies use the phase I to evaluate a drug’s toxicity and tolerability, Dr. Dan Von Hoff advocates that it can also provide valuable efficacy data and a compelling rationale for further study and investment, which ultimately leads to improved patient care.
Phoenix AZ — December 22, 2008 — Cancer drug developers traditionally use the phase I trial solely to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a drug. Today, Medelis has published a free new downloadable abstract, "The Lost Opportunity in Phase I Oncology Trials," an interview with renowned oncology investigator Daniel D. Von Hoff, M.D. In the abstract, he advocates for a phase I approach that looks beyond toxicity and gleans meaningful efficacy data, creating a more compelling rationale for further investment and improved patient care.
Medelis Expands Worldwide CRO Services with New European Division Led by Deirdre Tessman, Ph.D.
Medelis Europe offers complete oncology drug development services from preclinical through phase III
Phoenix AZ — October 7, 2008 — Medelis, Inc. today announced the formation of Medelis Europe and the appointment of Deirdre Tessman, Ph.D. as its Managing Director. Formerly of Tessman Technology Ltd. and ILEX Pharmaceuticals, Dr. Tessman brings more than 30 years of worldwide drug development and regulatory experience to the Medelis organization. She has directed all phases of pharmaceutical development from research through drug approval and marketing with additional expertise in the startup and turnaround of pharmaceutical companies.
Medelis Hires VP Preclinical Studies, Adds Oncology Preclinical Research Services to CRO Portfolio
Mike McGarry, Ph.D. will lead preclinical program design, management and execution for biotech clients
Phoenix AZ — September 9, 2008 — Medelis, Inc., an oncology contract research organization (CRO) providing drug development and clinical trial management services, today announced that Mike McGarry, Ph.D. has joined the company as Vice President of Preclinical Studies. Dr. McGarry, a preclinical research scientist with over 35 years of experience generating animal-based data, will lead a new service offering to provide preclinical study design, management and execution on behalf of Medelis’ biotech clients around the world.
Medelis Publishes 'Preclinical Trials: A Nuanced Approach to Get Into the Clinic Faster'
Phoenix AZ — September 4, 2008 — Medelis, Inc., a contract research organization providing complete oncology clinical trial design, management and execution, today published a free new downloadable abstract, "Preclinical Trials: A Nuanced Approach to Get Into the Clinic Faster," an interview with Mike McGarry, Ph.D.
Dr. McGarry is a preclinical research scientist with 35 years of experience generating high quality animal-based data. In the interview, he describes a nuanced preclinical process that can help a Chief Medical Officer (CMO) get into the clinic faster. This approach hinges on a strategic, well-defined rodent model, quality data, and ongoing integration between the pre-clinical, regulatory and clinical teams.